फार्माकोइकोनॉमिक्स: ओपन एक्सेस

Treatment Pathways and Associated Costs of Advanced or Metastatic ALK＋ Non-Small Cell Lung Cancer in Greece

Abstract

Maria Geitona,Hara Kousoulakou,Ioannis Boukovinas,Vassilios Georgoulias,Paraskevas Kosmidis,Georgios Koumakis,Dimitrios Krikelis,Argyro Markouri*,Paris Makrantonakis,Epaminondas Samantas,Konstantinos Syrigos

Objective: To investigate the resource use and costs associated with the management of metastatic anaplastic lymphoma kinase inhibitors (ALK+) NSCLC in Greece. Methods: The resource use was based on the outcomes of a Delphi panel with seven oncologists and unit costs derived from officially published sources. Results: The average per patient cost in the current treatment pathway (chemotherapy, crizotinib, chemotherapy, palliative care) was estimated at €67,391. The average per patient cost in future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care) was estimated at €104,571 (treatment duration 26 months) while in future scenario 2 (chemotherapy, ceritinib, chemotherapy, palliative care) was estimated at €134,215 (treatment duration 29.3 months). Conclusion: Ceritinib as second line treatment leads to an increase in total costs reflecting the longer survival